A second deal in a week for a voucher that speeds drug review could bring Ultragenyx $203 million.
Ultragenyx Pharmaceutical Inc. (RARE) announced a $203 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). This is the company's second PRV sale in a week, with proceeds aimed at funding innovative treatments and supporting profitability. The transaction is subject to customary closing conditions, including antitrust review. Jefferies LLC and Gibson, Dunn and Crutcher LLP are advising Ultragenyx on the deal.
How this was made
The 30-second read
Why it matters
The $203 M voucher sale improves liquidity, may accelerate R&D spending, and could lift the share price.
Market read
First disclosure of a sizable PRV sale; investors may re‑price the stock based on the new cash inflow.
What to watch
Potential antitrust delays under the Hart‑Scott‑Rodino Act could postpone cash receipt.
Background
Ultragenyx uses FDA Priority Review Vouchers to generate non‑dilutive capital for its rare‑disease pipeline.
Ticker impact
Ultragenyx Pharmaceutical announced the sale of a Rare Pediatric Disease Priority Review Voucher for $203 million, providing non‑dilutive funding.
likely upward pressure as investors price in the non‑dilutive funding boost
Voucher sale adds significant cash without equity dilution, improving financial outlook and reducing risk.
Market effects
Highlights continued demand for PRV transactions in the rare‑disease biotech sector, potentially encouraging similar deals.
US biotech market may see modest uplift as investors view voucher sales as a financing tool.
Limited to biotech investors; no broad macro impact.
Counterpoint
If the voucher sale signals cash‑flow pressure, the stock could face downside if future pipelines underperform.
Key entities
- companyUltragenyx Pharmaceutical Inc.
Biopharma focused on rare and ultra‑rare genetic diseases.
- advisorJefferies LLC
Exclusive financial advisor for the voucher transaction.
